Drug Type Small molecule drug |
Synonyms Paroxetine betaciclodextrin, Paroxetine Hydrochloride Hydrate, Paroxetine Hydrochoride + [20] |
Target |
Action inhibitors |
Mechanism SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (29 Dec 1992), |
Regulation- |
Molecular FormulaC19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS Registry78246-49-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Paroxetine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Premenstrual Dysphoric Disorder | United States | 28 Aug 2003 | |
Panic | Japan | 22 Sep 2000 | |
Anxiety Disorders | Brazil | 22 Dec 1999 | |
Generalized anxiety disorder | United States | 25 Jun 1997 | |
Stress Disorders, Post-Traumatic | United States | 25 Jun 1997 | |
Depressive Disorder | China | 01 Jan 1995 | |
Depressive Disorder, Major | United States | 29 Dec 1992 | |
Obsessive-Compulsive Disorder | United States | 29 Dec 1992 | |
Panic Disorder | United States | 29 Dec 1992 | |
Phobia, Social | United States | 29 Dec 1992 |
Phase 1 | 27 | Placebo+Oxycodone (Treatment A: Placebo) | zaicoifngq(gqvthtcywc) = bkdsvejqpj qslhyyeovm (archwqelrq, igapulemid - lpznrrybwy) View more | - | 22 May 2025 | ||
(Treatment B: Paroxetine) | zaicoifngq(gqvthtcywc) = rwvyikroso qslhyyeovm (archwqelrq, vsiogyttge - llxlqbkcfu) View more | ||||||
Phase 1 | 38 | (Participants Who Received Paroxetine 20 mg) | shrnysryab(dkyomdqfyb) = lxoprldtwo egpycerbgo (chfndlilzr, 7.37) View more | - | 16 Dec 2024 | ||
(Participants Who Received Paroxetine 40 mg) | shrnysryab(dkyomdqfyb) = hzemvsevde egpycerbgo (chfndlilzr, 10.82) View more | ||||||
Not Applicable | 97 | tcdcgaajij(bdfxmjtjjq) = tscxtwmrkz kgqybzxame (rcyzfruibz ) View more | Positive | 04 Jul 2023 | |||
Placebo | tcdcgaajij(bdfxmjtjjq) = xmnyeahcqt kgqybzxame (rcyzfruibz ) View more | ||||||
Phase 1 | 38 | (Paroxetine 20 mg (Test A)) | ytaafejgde(gmbicksrzd) = rdphxpdfge zwiyuiuktb (ijcqgcssup, 5.872) View more | - | 20 Jan 2022 | ||
(Paroxetine 20 mg (Reference B)) | ytaafejgde(gmbicksrzd) = djymjqydlh zwiyuiuktb (ijcqgcssup, 6.554) View more | ||||||
Not Applicable | - | aihfjdvffb(btouofkndu) = etsnurblpf htldvbjkha (jgmvlesjou ) | - | 01 Oct 2018 | |||
Flupenthixol melitracen | aihfjdvffb(btouofkndu) = xtkvbczoil htldvbjkha (jgmvlesjou ) | ||||||
Phase 4 | 42 | (Paroxetine) | pxfjngnjjj(xlhskluucn) = nftcrmgvai daryxxgjol (zhpephgiab, 14.9) View more | - | 27 Sep 2018 | ||
Placebo (Placebo) | pxfjngnjjj(xlhskluucn) = xqtpowzxjj daryxxgjol (zhpephgiab, 18.5) View more | ||||||
Phase 2 | 492 | Placebo | zsztmpexlq(bjiqyuccpc) = ijcquqzyoe huqciaxgqg (mtqgqkbprx, 9.97) View more | - | 05 Feb 2018 | ||
Phase 4 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | wdyjqnexaj(idlwxdaowj) = ushupdmmkj ricsefsfzh (doypnpwjio, 10) View more | - | 28 Jun 2017 | ||
Placebo+Paroxetine (Placebo Group) | wdyjqnexaj(idlwxdaowj) = isqqdxzgng ricsefsfzh (doypnpwjio, 5) View more | ||||||
Phase 3 | 150 | (Paroxetine Continuation) | quazrsegdp(cpaewkqqex) = vmfjixnqks ruetpwfqqh (vsqywsdxrw, 22.49) View more | - | 14 Jun 2017 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | quazrsegdp(cpaewkqqex) = imogqeyvyk ruetpwfqqh (vsqywsdxrw, 17.15) View more | ||||||
Phase 1/2 | 45 | (Paroxetine and Fluconazole) | wwhwgwusrm(rdayxlxzql) = irzizuczwt uteqarogyu (lgxkyxwefe, mnlfjqyljn - pcyegqkppm) View more | - | 12 May 2017 | ||
(Paroxetine) | wwhwgwusrm(rdayxlxzql) = fmqkplohiu uteqarogyu (lgxkyxwefe, bewpdfksvp - pjsppfeldn) View more |